The 10 Medicare Negotiated Drug Prices Starting in 2026

For the first time in the history of the program, Medicare has negotiated the prices it pays for a set of prescription drugs. The Inflation Reduction Act gave Medicare that authority, and the first 10 negotiated prices take effect on January 1, 2026. These are not obscure medications. They include some of the most widely prescribed drugs in the country for blood clots, diabetes, heart failure, and autoimmune conditions. If you take any of them, this is worth understanding, though the way it affects your own wallet is a little more nuanced than the headlines suggest.

Bryce's Take

The negotiated prices are genuinely good news, but the question I get is always the same: does this lower my copay to X dollars? And the honest answer is that it depends on your plan, because negotiation changes what Medicare pays, while your tier and cost-sharing decide what you pay. The bigger everyday protection for most of my clients is still the $2,000 annual cap that started in 2025. If you take Eliquis, Jardiance, Entresto, or any of these, let us look at your actual plan together so you are not guessing.

Which 10 drugs were negotiated

Medicare selected the first 10 Part D drugs for negotiation based on how much the program spends on them and how long they have been on the market without competition. The new negotiated prices apply starting January 1, 2026. Here is the full list and what each one treats.

The list at a glance

What negotiation actually means for you

The negotiation lowers the price Medicare and your Part D plan pay for these drugs. That is a real change, but it does not automatically translate into a fixed dollar savings at your pharmacy counter, because your out-of-pocket cost still depends on your specific plan's formulary, your tier placement, and your cost-sharing structure. A lower underlying price generally helps, and over time it tends to ease pressure on premiums and cost-sharing across the program. But two people on the same drug can still pay different amounts depending on which plan they chose. That is why checking your own plan matters more than reading a national average.

How this stacks on top of the $2,000 cap

The negotiated prices arrive alongside another major change that began in 2025: the $2,000 annual out-of-pocket cap on Part D covered drugs. Once your covered drug cost-sharing hits $2,000 in a plan year, you pay nothing more for the rest of that year. For someone taking one of these negotiated drugs plus a few others, the cap is often the bigger protection, because it limits your total exposure regardless of any single drug's price. The negotiated prices and the cap work together: lower list prices can slow how fast you reach the cap, and the cap stops your spending cold once you get there.

This is a rolling process, not a one-time event

These 10 drugs are only the first round. Medicare has already selected a second group of drugs for negotiation in later years, and the program is designed to keep adding drugs over time. So the list you see today will grow. If your medication is not on the current list, it may be a candidate in a future round. None of this changes the basic move you should make each year, which is to confirm your specific drugs are still well covered on your specific plan, because formularies and cost-sharing change every January.

What to do if you take one of these drugs

First, do not assume the negotiated price means your copay drops to some specific number, because your actual cost depends on your plan. Second, during the Annual Enrollment Period each fall, compare plans based on your exact medication list, not on premium alone. A plan with a slightly higher premium can easily be cheaper overall if it places your drug on a better tier. Third, if your out-of-pocket costs are high, remember the $2,000 cap and check whether you qualify for Extra Help. This is exactly the kind of comparison where a quick call can save you real money.

Bryce Casson

Licensed Independent Medicare Broker

Bryce Casson is an independent Medicare insurance broker who works with every major carrier. He does not represent any single insurer, which means his recommendations are based on what actually fits each client's situation, not on commissions or quotas.